Immuneering Corp (IMRX)vsRevolution Medicines Inc (RVMD)
IMRX
Immuneering Corp
$5.20
+2.56%
HEALTHCARE · Cap: $291.79M
RVMD
Revolution Medicines Inc
$202.00
-1.59%
HEALTHCARE · Cap: $39.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 162977% more annual revenue ($742,000 vs $455). RVMD leads profitability with a 0.0% profit margin vs 0.0%. IMRX earns a higher WallStSmart Score of 26/100 (F).
IMRX
Avoid26
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRX
The strongest argument for IMRX centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : IMRX
The primary concerns for IMRX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.38 — expect wider price swings.
RVMD is growing revenue faster at -95.2% — sustainability is the question.
IMRX generates stronger free cash flow (-19M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IMRX scores higher overall (26/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuneering Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug discovery platforms. Leveraging sophisticated bioinformatics and machine learning, the company focuses on identifying and refining drug candidates that selectively intervene in pivotal biological pathways, thereby enhancing efficacy and reducing toxicity. With a robust pipeline of novel therapies and strategic alliances, Immuneering is well-positioned to thrive in the rapidly evolving domains of personalized medicine and targeted oncology, offering significant investment opportunities for institutional investors.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?